ERBB2 and pancreatic neoplasm: In a recent phase II study in 21 patients with metastasized HER2 overexpressing (grade 2–3) pancreatic cancer a combination of trastuzumab and capecitabine resulted in partial remission rates of 24% and 50% of patients showed a reduction of the tumor marker CA19-9 [17].